Revelation Biosciences' PRIME Study Shows Promising Results for Gemini in Inflammatory Diseases

Revelation Biosciences, Inc. has announced positive results from its Phase 1b PRIME clinical study, focusing on the inflammatory treatment Gemini in stage 3 and 4 chronic kidney disease (CKD) patients. The study demonstrated Gemini's potential to normalize inflammatory response at the cellular level. The primary aim of assessing safety and tolerability of escalating doses was achieved.

Gemini notably decreased inflammatory activity and restored normal cellular response, indicated by peripheral blood mononuclear cell (PBMC) analysis over a week post-dose. These effects suggest Gemini's promising role in treating acute and chronic inflammation. The study involved 40 participants across several dose levels.

The market responded to Revelation's webcast update on September 10, 2025. Full data analysis and publication efforts are underway. The company plans to meet with the FDA for further program development discussions. No serious adverse events were reported during the study, marking a significant advance for Gemini's future applications.